Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma

被引：0

作者：

Miguel, Jesus F. San ^{[1
]}

Schlag, Rudolf ^{[2
]}

Khuageva, Nuriet K. ^{[3
]}

Dimopoulos, Meletios A. ^{[4
]}

Shpilberg, Ofer ^{[5
]}

Kropff, Martin H. ^{[6
]}

Spicka, Ivan ^{[7
]}

Petrucci, Maria Teresa ^{[8
]}

Palumbo, Antonio ^{[9
]}

Samoilova, Olga S. ^{[10
]}

Dmoszynska, Anna ^{[11
]}

Abdulkadyrov, Kudrat M. ^{[12
]}

Schots, Rik ^{[13
]}

Jiang, Bin ^{[14
]}

Mateos, Maria-Victoria ^{[15
]}

Anderson, Kenneth C. ^{[16
]}

Esseltine, Dixie-Lee ^{[17
]}

Liu, Kevin ^{[18
]}

Cakana, Andrew ^{[19
]}

van de Velde, Helgi ^{[19
]}

Richardson, Paul

机构：

[1] USAL, CSIC, IBMCC, CIC,Hosp Univ Salamanca, Salamanca, Spain

[2] Praxis Hematol & Oncol, Wurzburg, Germany

[3] SP Botkin Moscow City Clin Hosp, Dept Hematol, Moscow, Russia

[4] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece

[5] Rabin Med Ctr, Petah Tiqwa, Israel

[6] Univ Munster, Munster, Germany

[7] Charles Univ Praha, Dept Int Med 1, Prague, Czech Republic

[8] Univ Roma La Sapienza, Rome, Italy

[9] Univ Turin, Div Ematol, AOU San Giovanni Battista, Turin, Italy

[10] Nizhnii Novgorod Reg Clin Hosp, Nizhnii Novgorod, Russia

[11] Med Univ Lublin, Lublin, Poland

[12] St Petersburg Clin Res Inst Hematol & Transfusiol, St Petersburg, Russia

[13] Belgian Hematol Soc, Myeloma Study Grp, Brussels, Belgium

[14] Peking Univ, Peoples Hosp, Beijing, Peoples R China

[15] Hosp Univ Salamanca, Salamanca, Spain

[16] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Dis Ctr, Boston, MA 02115 USA

[17] Takeda Oncol Co, Millennium Pharmaceut, Cambridge, MA USA

[18] Johnson & Johnson Pharmaceut Res & Dev, Raritan, NJ USA

[19] Johnson & Johnson Pharmaceut Res & Dev, Dept Clin R&D Oncol, Beerse, Belgium

来源：

BLOOD | 2008年 / 112卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：242 / 242

页数：1

共 50 条

[41] Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study
Morabito, Fortunato
Bringhen, Sara
Larocca, Alessandra
Wijermans, Pierre
Victoria Mateos, Maria
Gimsing, Peter
Mazzone, Carla
Gottardi, Daniela
Omede, Paola
Zweegman, Sonja
Jose Lahuerta, Juan
Zambello, Renato
Musto, Pellegrino
Magarotto, Valeria
Schaafsma, Martijn
Oriol, Albert
Juliusson, Gunnar
Cerrato, Chiara
Catalano, Lucio
Gentile, Massimo
Isabel Turel, Ana
Liberati, Anna Marina
Cavalli, Maide
Rossi, Davide
Passera, Roberto
Rosso, Stefano
Beksac, Meral
Cavo, Michele
Waage, Anders
San Miguel, Jesus
Boccadoro, Mario
Sonneveld, Pieter
Palumbo, Antonio
Offidani, Massimo
AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 355 - 362
[42] Superiority of melphalan-prednisone (MP) plus thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma
Facon, T.
Mary, J.
Harousseau, J.
Huguet, F.
Berthou, C.
Grosbois, B.
Anglaret, B.
Azzedine, A.
Rodon, P.
ANNALS OF ONCOLOGY, 2006, 17 : 54 - 54
[43] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Fu, Weijun
Bang, Soo-Mee
Huang, Honghui
Kim, Kihyun
Li, Wei
An, Gang
Lee, Je-Jung
Cai, Zhen
Jin, Jie
Wang, Yafei
Chim, Chor Sang
Carson, Robin
Liu, Rui
Zhao, Man
Chen, Xi
Cui, Canchan
Hou, Jian
Wang, Jianxiang
ANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525
[44] DARATUMUMAB PLUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (D-VMP) VERSUS BORTEZOMIB, MELPHALAN, AND PREDNISONE (VMP) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS (PTS) INELIGIBLE FOR TRANSPLANT: A PHASE 3 RANDOMIZED STUDY (ALCYONE)
Mateos, M., V
Dimopoulos, M. A.
Cavo, M.
Suzuki, K.
Jakubowiak, A.
Knop, S.
Doyen, C.
Lucio, P.
Nagy, Z.
Kaplan, P.
Pou
Cook, M.
Grosicki, S.
Crepaldi, A.
Liberati, A. M.
Campbell, P.
Shelekhova, T.
Yoon, S. S.
Iosava, G.
Fujisaki, T.
Garg, M.
Chiu, C.
Wang, J.
Carson, R.
Crist, W.
Deraedt, W.
Nguyen, H.
Qi, M.
San-Miguel, J.
HAEMATOLOGICA, 2018, 103 : 22 - 22
[45] Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)
Mateos, Maria-Victoria
Dimopoulos, Meletios A.
Cavo, Michele
Suzuki, Kenshi
Jakubowiak, Andrzej J.
Knop, Stefan
Doyen, Chantal
Lucio, Paulo
Nagy, Zsolt
Kaplan, Polina
Pour, Ludek
Cook, Mark
Grosicki, Sebastian
Crepaldi, Andre H.
Liberati, Anna Marina
Campbell, Philip
Shelekhova, Tatiana
Yoon, Sung-Soo
Iosava, Genadi
Fujisaki, Tomoaki
Garg, Mamta
Chiu, Christopher
Wang, Jianping
Carson, Robin
Crist, Wendy
Deraedt, William
Nguyen, Marie
Qi, Ming
San-Miguel, Jesus F.
BLOOD, 2017, 130
[46] Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study
Dimopoulos, Meletios A.
Richardson, Paul
Schlag, Rudolf
Khuageva, Nuriet K.
Shpilberg, Ofer
Kastritis, Efstathios
Kropff, Martin H.
Petrucci, Maria Teresa
Delforge, Michel
Alexeeva, Julia A.
Schots, Rik
Masszi, Tamas
Mateos, Maria-Victoria
Deraedt, William
Liu, Kevin
Cakana, Andrew
van de Velde, Helgi
Miguel, Jesus F. San
BLOOD, 2008, 112 (11) : 608 - 609
[47] Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.
Kolb, Brigitte
Hulin, Cyrille
Caillot, Denis
Benboubker, Lotfi
Tiab, Mourad
Blin, Nicolas
Leleu, Xavier
Roussel, Murielle
Attal, Michel
Facon, Thierry
Moreau, Philippe
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[48] Phase III trial evaluating bortezomib in addition to melphalan/prednisone in newly diagnosed patients ineligible for transplantation
Muneer, Sabeeha
Cunningham, Sonia
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 18 - 20
[49] At Extended Follow-up, First-Line Bortezomib plus Melphalan/Prednisone Continues to Yield Survival Benefit over Melphalan/Prednisone in Transplantation-Ineligible Multiple Myeloma
不详
CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (02): : 124 - 125
[50] A prospective randomized controlled trial of oral melphalan, prednisone, thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients
Palumbo, A.
Aitoro, G.
Bringhen, S.
Caravita, T.
Callea, V.
Zambello, R.
Pregno, P.
Carubelli, A.
Baraldi, A.
Cellini, C.
Dore, F.
Piro, E.
Ambrosini, M. T.
Musto, P.
Liberati, A. M.
Boccadoro, M.
ANNALS OF ONCOLOGY, 2006, 17 : VII161 - VII161

← 1 2 3 4 5 →